Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R follicular lymphoma: phase 1/2 BRUIN study. - Shah NN; Zinzani PL; Wang M; Nasta SD; Lech-Maranda E; Ogawa Y; Fakhri B; Kuss B; Miyashita K; Patel K; Coombs CC; Ma S; et al. (Blood advances, 2025)